Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) has been assigned a $24.00 target price by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday. The brokerage presently has a “hold” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 0.17% from the company’s previous close.

A number of other research analysts also recently commented on VRX. Vetr upgraded Valeant Pharmaceuticals Intl from a “strong sell” rating to a “sell” rating and set a $12.46 target price on the stock in a research note on Monday, September 18th. Deutsche Bank restated a “hold” rating and issued a $19.00 target price on shares of Valeant Pharmaceuticals Intl in a research note on Monday, September 25th. Cantor Fitzgerald restated a “buy” rating and issued a $23.00 target price on shares of Valeant Pharmaceuticals Intl in a research note on Thursday, September 28th. Wells Fargo & Co restated an “underperform” rating and issued a $8.00 target price on shares of Valeant Pharmaceuticals Intl in a research note on Saturday, September 30th. Finally, ValuEngine upgraded Valeant Pharmaceuticals Intl from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Six research analysts have rated the stock with a sell rating, nine have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Valeant Pharmaceuticals Intl has an average rating of “Hold” and an average target price of $18.56.

Shares of Valeant Pharmaceuticals Intl (VRX) traded up $0.12 during midday trading on Tuesday, reaching $23.96. The company’s stock had a trading volume of 3,203,024 shares, compared to its average volume of 14,910,855. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 4.84. Valeant Pharmaceuticals Intl has a 1 year low of $8.31 and a 1 year high of $24.43. The stock has a market capitalization of $8,600.00, a P/E ratio of 6.14, a P/E/G ratio of 0.73 and a beta of -0.22.

Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last issued its earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.14. Valeant Pharmaceuticals Intl had a return on equity of 51.56% and a net margin of 15.35%. equities research analysts forecast that Valeant Pharmaceuticals Intl will post 3.82 EPS for the current fiscal year.

In related news, Director John Paulson purchased 344,216 shares of the firm’s stock in a transaction dated Thursday, November 16th. The stock was bought at an average price of $14.40 per share, for a total transaction of $4,956,710.40. Following the purchase, the director now owns 94,559 shares in the company, valued at approximately $1,361,649.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 5.87% of the company’s stock.

A number of large investors have recently made changes to their positions in VRX. Dimensional Fund Advisors LP boosted its stake in Valeant Pharmaceuticals Intl by 327.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 4,472,185 shares of the specialty pharmaceutical company’s stock valued at $64,086,000 after purchasing an additional 3,426,410 shares during the period. Paulson & CO. Inc. boosted its stake in Valeant Pharmaceuticals Intl by 12.5% during the 2nd quarter. Paulson & CO. Inc. now owns 21,813,400 shares of the specialty pharmaceutical company’s stock valued at $377,372,000 after purchasing an additional 2,428,900 shares during the period. Renaissance Technologies LLC bought a new stake in Valeant Pharmaceuticals Intl during the 2nd quarter valued at approximately $41,574,000. Beach Point Capital Management LP bought a new stake in Valeant Pharmaceuticals Intl during the 3rd quarter valued at approximately $15,670,000. Finally, Gotham Asset Management LLC bought a new stake in Valeant Pharmaceuticals Intl during the 2nd quarter valued at approximately $14,239,000. Hedge funds and other institutional investors own 49.45% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first reported by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2018/01/16/valeant-pharmaceuticals-intl-vrx-given-hold-rating-at-hc-wainwright.html.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals Intl (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.